To gain insights into the role of MYC target gene activation in TME interactions we examined 27,837 malignant cells and 3,715 cells from the TME (comprising T, and myeloid cells) in CLL phase and 7,479 cells after RT and 1694 TME derived from four samples (Figures 2a,b; Supplementary Figures S3a,b). This evidence concerns the gene MYC and B-cell chronic lymphocytic leukemia.